Ludwig-Maximilians-University (LMU) is the leading teaching and research university in Germany, ranking 1st in Germany in the latest Times Higher Education World University Ranking. With the neighbouring Max-Planck, Helmholtz, and Technical University institutions, it constitutes a major European science hub.

The Department of Infectious Disease & Tropical Medicine has a very active outpatient department and one of Europe’s largest international clinical trials units, conducting clinical regulated and non-regulated studies in 18 different countries in Africa, Asia and South America. In cooperation with other partners at the University. Its main activities are in tuberculosis, HIV, neglected tropical diseases and emerging infections. It also hosts the international clinical trials unit for the German Center for Infection Research (DZIF) an association of 40 leading infectious disease research institutions in Germany and supported by the German government. The department is strongly committed in the training and capacity building of international researchers through its master and PhD programmes in international health.

The department is carrying out TB research since 2006. So far, team members of the department have been conducting more than 20 TB clinical trials as either sponsor representatives or principle investigators. It is internationally renowned for its innovations in clinical trial design, and for effective implementation of these innovations into high-quality clinical trials. Michael Hoelscher is one of three Chief Investigators of PanACEA, Europe’s largest clinical TB drug development network with more than 3,000 patients enrolled so far. Together with the Hans-Knöll-Institute and the German Center for Infection Research, the department has its own TB drug development programme, with BTZ043 starting Phase IIa trials in Q3 2019. The department has also significant expertise in the evaluation of novel TB diagnostic methods and is conducting the largest study on long term sequalae of tuberculosis, and the largest study evaluating several new tests as TB diagnostics and treatment response markers in children.